Several medications have individually been shown to reduce mortality in patients with acute
coronary syndromes (ACS), but data on long-term outcomes related to the use of …

Background—Several individual pharmacological agents, such as antiplatelet drugs, β-
blockers, ACE inhibitors, and lipid-lowering agents, have proven efficacy in reducing …

Aim To evaluate the prevalence and impact of the prescribing of an evidence‐based cardiac
medication (EBM) combination on 1‐month, 6‐months, and 12‐months all‐cause mortality in …

Objectives. The purpose of this study to determine whether use of cardiac medications
reflects evidence-based recommendations for patients with non–ST elevation acute …

METHODS There were 1358 patients who were admitted to, or discharged from, inpatient
services at the University of Michigan Medical Center from 1 January 1999 to 11 March 2002 …

Background Use of the four evidence-based medications [EBMs: antiplatelet agent, beta-
blocker, statin and angiotensin-converting enzyme inhibitor or angiotensin receptor blocker …

Use of evidence-based medicine (EBM) improves outcomes after acute coronary syndromes
(ACS), yet patients often discontinue prescribed therapies after discharge. Although such …

OBJECTIVE: To analyse long-term adherence persistence of evidence-based medical
therapy in 'real-world'patients with coronary disease. METHODS: Cardiologists recruited the …

Background—Acute coronary syndrome (ACS) patients in the highest risk categories are
least likely to receive evidence-based treatments (EBTs). We sought to determine why …

BACKGROUND: Current practice guidelines suggest routine use of several effective cardiac
medications in hospital survivors of acute myocardial infarction (AMI). The objectives of our …